Business Wire

The Estée Lauder Companies Announces Retirement of Alexandra Trower, Executive Vice President, Global Communications

12.4.2021 14:00:00 EEST | Business Wire | Press release

Share

Today, The Estée Lauder Companies (NYSE:EL) (ELC) announced that after 13 years with the company, Alexandra (Alex) Trower, Executive Vice President, Global Communications, will retire effective July 1, 2021. The successor to Alex’s role will be announced at a later date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005450/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alex Trower, Executive Vice President, Global Communications, The Estée Lauder Companies, announces retirement. (Photo: Business Wire)

“Alex has been a highly respected thought-leader, collaborative partner, and a trusted senior business advisor,” said Fabrizio Freda, President and CEO, The Estée Lauder Companies. “Leveraging her deep expertise across financial, corporate, consumer and crisis communications, Alex has continuously evolved our strategic communications priorities to drive and support the rapid growth of our business. She built a truly outstanding, global, multi-disciplinary organization and has led her team with wisdom and grace, continuously strengthening the delicate balance of art and science that is ever-present in the world of communications.”

William P. Lauder, Executive Chairman, The Estée Lauder Companies, added: “Against the backdrop of an increasingly complex global landscape, Alex has delivered thoughtful, effective communications to our valued stakeholders, strategically elevating our winning business narrative, rich culture, compelling heritage and distinctive ELC brand equity. She is an outstanding communicator and skilled strategist, and her incredible character, steadfast integrity and deep empathy will be greatly missed across the organization.”

Since joining The Estée Lauder Companies in 2008, Alex has been the architect of ELC’s Global Communications function as it stands today: a highly operationalized, flexible, worldwide and regional structure that prioritizes local relevance, functional expertise and brand-building acumen. Under her leadership, Global Communications has strategically expanded across regions; and through close partnership with regional and affiliate leaders, the department plays a critical role in supporting the company's continued strong regional growth.

Among her many accomplishments, Alex has strategically elevated the company’s reputation worldwide. In 2016, she oversaw the launch of the company’s refreshed Corporate Brand, which represented a transformational change in where, how and why the company engages with its stakeholders. Through this lens, Alex and her team have enabled the organization to communicate boldly, quickly and in more intentional and transparent ways, with an emphasis on strengthening and modernizing the platforms that most resonate with its audiences.

Alex has been a champion of ELC’s efforts across philanthropy, Citizenship and Sustainability, and Inclusion, Diversity and Equity. She serves as a Board member of The Estée Lauder Companies’ Charitable Foundation, is a founding member of the company’s Diversity Council, and served as the first Executive Co-Sponsor of wELCome, the company’s LGBTQA employee resource group.

Mentoring, leading and cultivating talented women is Alex’s passion, which was borne out of her experience as a student at Hollins University, one of the country’s leading women’s universities, where she now serves as the Chair of the Board of Trustees. In 2018, Alex was recognized by New York Women in Communications with a prestigious Matrix Award, presented to her by William P. Lauder in recognition of her exceptional leadership and contributions across the industry. She served as the Co-Chair of the Board of Directors for the International Women’s Media Foundation (IWMF), which supports female journalists worldwide. In 2014, she received the IWMF’s Corporate Leadership Award in recognition of her more than 15 years of service and fundraising.

“I am incredibly proud of all that my team and I have accomplished,” said Alex Trower. “ELC’s Global Communications organization has consistently advanced ahead of the curve, seamlessly partnering with stakeholders across the company and the industry to drive and support the continued success of our business. While the decision to retire is of course bittersweet, I know that the talented Global Communications team is well positioned for its next chapter of growth. On a personal note, it has been an absolute pleasure to serve in this role alongside the Lauder Family and the exceptional ELC executive leadership team.”

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-L
ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Rainey Mancini
(212) 284-3049

Media Relations:
Jill Marvin
(212) 572-4438

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye